Modalis unveils primate data showing safe LAMA1 gene activation for LAMA2-CMD. Find out what it means for CRISPR therapeutics and CMD patients.
QurAlis confirms target engagement of QRL-101 in ALS patients. Find out what this means for epilepsy trials and Kv7-targeted drug development.
Johnson & Johnson’s $3B Halda acquisition brings RIPTACs into focus. Find out what it means for prostate cancer therapy and precision oncology.
Genmab ends development of acasunlimab to focus on EPKINLY, petosemtamab, and Rina-S. Find out what this shift means for 4-1BB bispecifics today.
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.
NeoImmuneTech takes over U.S. rights for Endari from Emmaus Life Sciences. Find out what this deal reveals about the future of sickle cell treatment.
New Phase 3 subgroup data suggest Delcath’s HEPZATO KIT improves survival in patients with lower tumor burden or LDH. Learn what this means for mUM treatment.
USDA approves Elanco’s Befrena for canine allergic dermatitis. Find out what it means for vets, pet owners, and the mAb dermatology race.
AstraZeneca PLC and Daiichi Sankyo’s HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for use in patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment and are at high risk of recurrence. The designation is based on positive results […]
Sinopia Biosciences receives NIH grant to expand its LEADS platform. Find out how AI and metabolomics could transform drug discovery.